Brief: Freenome Expands Personalized Cancer Detection Portfolio With Simplescreen Lung Test
Tue 13:43
BRIEF-Freenome Expands Personalized Cancer Detection Portfolio With Simplescreen Lung Test Oct 20 (Reuters) - Freenome, Inc. FRNM.O:
EXPANDS PERSONALIZED CANCER DETECTION PORTFOLIO, LAUNCHING SIMPLESCREEN™ LUNG TEST WITH FDA-APPROVED SIMPLESCREEN CRC OPTION
Source text: ID:nGNX4kK10X
Further company coverage: FRNM.O
((Reutersbriefs@thomsonreuters.com;))
Recent news on Freenome
See all newsBrief: Freenome Expands Personalized Cancer Detection Portfolio With Simplescreen Lung Test
FDA approves Freenome's blood test for colorectal cancer screening (updated)
FDA approves Freenome's blood test for colorectal cancer screening
Brief: FDA Approves Freenome’S Simplescreen™ Crc Blood-Based Screening Test Abbott To Commercialize In The U.S.
Brief: Freenome And Perceptive Capital Solutions Corp Announce Business Combination Agreement